Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mosapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | HTR1A | P08908 | 1/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.84 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.84 |
| ▸ | HTR2C | P28335 | 1/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | HTR2B | P41595 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.84 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.84 |
| ▸ | DRD4 | P21917 | 12/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mosapride SCHEMBL6227414 | 1.00 | DRD3 (0.84) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL30450705 | 1.00 | DRD3 (0.84) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL1098769 | 1.00 | DRD3 (0.84) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL8462520 | 0.99 | DRD3 (0.85) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL258620 | 0.99 | DRD3 (0.85) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL2369236 | 0.92 | DRD3 (0.98) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6229365 | 0.92 | DRD3 (0.91) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL29400580 | 0.91 | DRD3 (1.00) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6228981 | 0.91 | DRD3 (1.00) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL16417 | 0.91 | DRD3 (1.00) | DRD3MEN1LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582606-B2 | Tablet and method for producing tablet | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-24 | — | — | US | disclosed |
| WO-2025047788-A1 | FILM PREPARATION HAVING ADHESIVENESS TO INSIDE OF ANIMAL ORAL CAVITY | 株式会社ペティーナ | 2025-03-06 | — | — | WO | disclosed |
| WO-2025047787-A1 | FILM PREPARATION CAPABLE OF ADHERING TO ANIMAL ORAL CAVITIES | 株式会社ペティーナ | 2025-03-06 | — | — | WO | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20220218616-A1 | TABLET AND METHOD FOR PRODUCING TABLET | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2022-07-14 | — | — | US | disclosed |
| US-11000481-B2 | Composite preparation of mosapride and rabeprazole | KOREA UNITED PHARM. INC. (KR) | 2021-05-11 | — | — | US | disclosed |
| US-10746721-B2 | Method for rapid testing allergy | Shibaguchi, Hirotomo (JP) | 2020-08-18 | — | — | US | disclosed |
| US-10746722-B2 | Method for rapid testing allergy | Shibaguchi, Hirotomo (JP) | 2020-08-18 | — | — | US | disclosed |
| US-20190265225-A1 | METHOD FOR RAPID TESTING ALLERGY | SHIBAGUCHI HIROTOMO (JP) | 2019-08-29 | — | — | US | disclosed |
| US-20190265224-A1 | METHOD FOR RAPID TESTING ALLERGY | SHIBAGUCHI HIROTOMO (US) | 2019-08-29 | — | — | US | disclosed |
| US-10324079-B2 | Method for rapid testing allergy | Shibaguchi, Hirotomo (JP) | 2019-06-18 | — | — | US | disclosed |
| CN-108289849-A | Compound preparation of mosapride and rabeprazole | 韩国联合制药株式会社 | 2018-07-17 | — | — | CN | disclosed |
| US-20180177731-A1 | Composite Preparation of Mosapride and Rabeprazole | KOREA UNITED PHARM. INC. (KR) | 2018-06-28 | — | — | US | disclosed |
| EP-2975403-B1 | RAPID ALLERGY TESTING METHOD | SHIBAGUCHI HIROTOMO (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-20160069858-A1 | RAPID ALLERGY TESTING METHOD | Shibaguchi, Hirotomo (JP) | 2016-03-10 | — | — | US | disclosed |
| EP-2975403-A1 | RAPID ALLERGY TESTING METHOD | Shibaguchi, Hirotomo (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2543366-A1 | FILM PREPARATION CONTAINING MEDICAMENT WITH UNPLEASANT TASTE | Kyukyu Pharmaceutical Co., Ltd. (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-20120328675-A1 | FILM PREPARATION CONTAINING MEDICAMENT WITH UNPLEASANT TASTE | KOWA CO., LTD. (JP) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582606-B2 | Tablet and method for producing tablet | GRHPR, RCC1, KIT | HTR4 1846/4885DRD3 4564/4885MEN1 3180/4885 |
| US-20180177731-A1 | Composite Preparation of Mosapride and Rabeprazole | MLNR, RAB14, RAB29 | HTR4 180/4885DRD3 1874/4885MEN1 1805/4885 |
| US-11000481-B2 | Composite preparation of mosapride and rabeprazole | MLNR, RAB14, RAB29 | HTR4 180/4885DRD3 1874/4885MEN1 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.